Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Bone Diseases, Developmental

ClinicalTrials.gov lists 1,034 trials for Bone Diseases, Developmental or a narrower condition beneath it. Novo Nordisk A/S has the most among industry and government lead sponsors, with 29.

MeSH D001848 Musculoskeletal Diseases C05
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 64 Phase 1/2 Phase 1/2 24 Phase 2 Phase 2 143 Phase 2/3 Phase 2/3 24 Phase 3 Phase 3 100 Phase 4 Phase 4 75 Not applicable Not applicable 225 Observational Observational 377 Phase 1 Phase 1 64 Phase 1/2 Phase 1/2 24 Phase 2 Phase 2 143 Phase 2/3 Phase 2/3 24 Phase 3 Phase 3 100 Phase 4 Phase 4 75 Not applicable Not applicable 225 Observational Observational 377

Trials per phase

1 more section with rows

14 of the 1,034 trials are tagged with Bone Diseases, Developmental itself; the rest are tagged with a narrower condition beneath it.

Get the Bone Diseases, Developmental report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Bone Diseases, Developmental trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 70

1991: 2 trials (Phase 3 1, Phase 2/3 1) 1992: 1 trials (Phase 2 1) 1993: 2 trials (Observational 2) 1994: 3 trials (Observational 2, Phase 1 1) 1995: 2 trials (Observational 1, Phase 1 1) 1996: 4 trials (Observational 4) 1997: 8 trials (Observational 4, Not applicable 1, Phase 3 3) 1998: 6 trials (Observational 4, Phase 4 1, Phase 2 1) 1999: 7 trials (Observational 3, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1 1) 2000: 7 trials (Observational 2, Phase 3 2, Phase 2/3 1, Phase 1 2) 2001: 10 trials (Observational 2, Not applicable 1, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 1) 2002: 15 trials (Observational 4, Not applicable 5, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 1) 2003: 26 trials (Observational 7, Not applicable 2, Phase 4 6, Phase 3 6, Phase 2/3 2, Phase 2 2, Phase 1 1) 2004: 29 trials (Observational 7, Not applicable 5, Phase 4 3, Phase 3 6, Phase 2 7, Phase 1 1) 2005: 29 trials (Observational 15, Not applicable 2, Phase 4 4, Phase 3 4, Phase 2 3, Phase 1 1) 2006: 21 trials (Observational 5, Not applicable 4, Phase 4 5, Phase 3 2, Phase 2 4, Phase 1 1) 2007: 35 trials (Observational 14, Not applicable 3, Phase 4 4, Phase 3 5, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2008: 27 trials (Observational 6, Not applicable 4, Phase 4 4, Phase 3 4, Phase 2/3 2, Phase 2 4, Phase 1/2 2, Phase 1 1) 2009: 26 trials (Observational 7, Not applicable 2, Phase 4 4, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1 4) 2010: 25 trials (Observational 9, Not applicable 2, Phase 4 1, Phase 3 6, Phase 2 4, Phase 1/2 1, Phase 1 2) 2011: 32 trials (Observational 10, Not applicable 5, Phase 4 4, Phase 3 2, Phase 2 6, Phase 1/2 1, Phase 1 4) 2012: 32 trials (Observational 13, Not applicable 6, Phase 4 3, Phase 2 5, Phase 1/2 1, Phase 1 4) 2013: 41 trials (Observational 15, Not applicable 11, Phase 4 4, Phase 3 2, Phase 2 6, Phase 1 3) 2014: 44 trials (Observational 12, Not applicable 13, Phase 4 4, Phase 3 1, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 2) 2015: 48 trials (Observational 15, Not applicable 10, Phase 4 4, Phase 3 7, Phase 2 5, Phase 1/2 2, Phase 1 5) 2016: 33 trials (Observational 11, Not applicable 8, Phase 4 3, Phase 3 2, Phase 2 8, Phase 1 1) 2017: 46 trials (Observational 14, Not applicable 10, Phase 4 2, Phase 3 6, Phase 2 8, Phase 1/2 1, Phase 1 5) 2018: 34 trials (Observational 11, Not applicable 10, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2019: 66 trials (Observational 25, Not applicable 20, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 9, Phase 1/2 4, Phase 1 1) 2020: 49 trials (Observational 15, Not applicable 12, Phase 4 1, Phase 3 2, Phase 2 11, Phase 1/2 3, Phase 1 5) 2021: 55 trials (Observational 29, Not applicable 13, Phase 4 1, Phase 3 2, Phase 2 6, Phase 1 4) 2022: 51 trials (Observational 18, Not applicable 18, Phase 4 3, Phase 3 1, Phase 2/3 1, Phase 2 8, Phase 1 2) 2023: 70 trials (Observational 31, Not applicable 19, Phase 4 4, Phase 3 4, Phase 2/3 2, Phase 2 4, Phase 1 6) 2024: 45 trials (Observational 19, Not applicable 13, Phase 3 5, Phase 2/3 1, Phase 2 6, Phase 1/2 1) 2025: 54 trials (Observational 27, Not applicable 12, Phase 4 1, Phase 3 3, Phase 2/3 3, Phase 2 4, Phase 1/2 2, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 35
2025 54
2024 45
2023 70
2022 51
2021 55
2020 49
2019 66
2018 34
2017 46

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 47 trials starting in 2026 and about 50 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 72 trials still running at the 2026-10-09 snapshot; registered median of 29 months across 611 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Bone Diseases, Developmental trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 64
Phase 1/2 24
Phase 2 143
Phase 2/3 24
Phase 3 100
Phase 4 75
Not applicable 225
Observational 377
Expanded access 2

How many Bone Diseases, Developmental trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 30
Recruiting 136
Enrolling by invitation 15
Active, not recruiting 55
Completed 540

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Bone Diseases, Developmental trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novo Nordisk A/S 29
Pfizer 24
Changchun GeneScience Pharmaceutical Co., Ltd. 18
BioMarin Pharmaceutical 16
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 16

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Bone Diseases, Developmental? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
BMN 111 11
Somapacitan 11
MOD-4023 8
Setrusumab 7
Somavaratan 6

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
somatropin AQ 110
PEG-somatropin 8
Low dose losartan 8
Test Euthyrox® 6
LUM-201 6

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Bone Diseases, Developmental trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 170 29
Pituitary tumour recurrent 136 2
Cerebrovascular accident 86 6
Pyrexia 84 17
Dehydration 80 12

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Bone Diseases, Developmental? (37)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Novel molecular mechanism in Malan syndrome uncovered through genome sequencing reanalysis, exon-level Array, and RNA sequencing. American journal of medical genetics. Part A 2024 Yes
Perioperative Interdisciplinary Intervention Contributes to Improved Outcomes of Adolescents Treated With Hip Preservation Surgery. Journal of pediatric orthopedics 2018 Yes
Rapid degradation of progressive ankylosis protein (ANKH) in craniometaphyseal dysplasia. Scientific reports 2018 Yes
Trans-oral fine needle aspiration cytology in cervical (C1 and C2) vertebral lesions: a novel diagnostic approach. Cytopathology : official journal of the British Society for Clinical Cytology 2017 Yes
Sphenoid dysplasia in neurofibromatosis type 1: a new technique for repair. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2017 Yes

Showing 5 of 37 publications.

Start your 14-day trial Email me all 37 publications as a PDF

Sub-conditions in MeSH (12)

MeSH descendants one level down with at least one trial, most trials first.

+2 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages